YK-11 is used in performance settings by individuals specifically seeking the myostatin inhibition effect on top of the androgen receptor activity. The theoretical appeal is significant — removing the natural ceiling on muscle growth is a compelling concept. In practice, the in vitro myostatin inhibition data has not been validated in human use, an...
YK-11 appears in stacks with other SARMs, most commonly RAD-140 or LGD-4033, by users who want to add the theoretical myostatin inhibition to an existing anabolic protocol. It is not a base compound. Given the complete absence of human safety data, combining it with other compounds makes the risk assessment even more complex....
YK-11 has the least human safety data of any commonly circulated performance compound. There are no human trials, no established safe dose ranges, no established contraindications, and no long-term safety data of any kind. The compounds structural similarity to steroids means it likely carries the s...